Pharmacy World & Science

, 32:26 | Cite as

CYP2D6*4, CYP3A5*3 and ABCB1 3435T polymorphisms and drug-related falls in elderly people

  • Maren I. Blonk
  • Nathalie van der Velde
  • Patricia M. L. A. van den Bemt
  • Ron H. N. van Schaik
  • Tischa J. M. van der CammenEmail author
Short Research Report


Objective The objective of this study is to investigate the association between CYP2D6*4, CYP3A5*3 and ABCB1 3435T polymorphisms and drug-related falls. Method Multivariate logistic regression was performed in an existing database in order to study the association between falls history and CYP2D6*4, CYP3A5*3, ABCB1 3435T polymorphisms in patients using fall-risk-increasing CYP2D6, CYP3A5 and P-glycoprotein (gene product of ABCB1) substrates. Results No statistically significant increased fall risk was found in ‘poor metabolizers’ compared to ‘extensive’ and ‘intermediate metabolizers’ using fall-risk-increasing CYP2D6 substrates (Odds ratio (OR) = 2.2; 95% confidence interval (CI) 0.2–25.0), CYP3A5 substrates (OR = 0.9; 95% CI 0.2–3.3) and P-glycoprotein substrates (OR = 2.1; 95% CI 0.2–17.2). Conclusion The hypothesis that ‘poor metabolizers’ have an increased fall risk was not confirmed. A larger study population is needed to confirm the potential association that was seen between CYP2D6*4 and ABCB1 3435T polymorphisms and drug-related falls.


ABCB1-3435T CYP2D6*4 CYP3A5*3 Elderly Fall-risk Drug use Falls Cytochrome P450 Polymorphism 



This study was funded by Erasmus University Medical Center and by funds of Merck Sharp and Dohme, and Will-Pharma. The study’s sponsors had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.

Conflicts of interest statement

The authors of this article have nothing to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this article.


  1. 1.
    Masud T, Morris RO. Epidemiology of falls. Age Ageing. 2001;30(Suppl 4):3–7.PubMedGoogle Scholar
  2. 2.
    Gillespie LD, Gillespie WJ, Robertson MC, Lamb SE, Cumming RG, Rowe BH. Interventions for preventing falls in elderly people. Cochrane Database Syst Rev. 2003;4:CD000340.Google Scholar
  3. 3.
    Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc. 1999;47(1):40–50.PubMedGoogle Scholar
  4. 4.
    Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc. 1999;47(1):30–9.PubMedGoogle Scholar
  5. 5.
    Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3(2):229–43.CrossRefPubMedGoogle Scholar
  6. 6.
    Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006;58(3):521–90.CrossRefPubMedGoogle Scholar
  7. 7.
    Chinn LW, Kroetz DL. ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther. 2007;81(2):265–9.CrossRefPubMedGoogle Scholar
  8. 8.
    van der Velde N, Stricker BH, Pols HA, van der Cammen TJ. Risk of falls after withdrawal of fall-risk-increasing drugs: a prospective cohort study. Br J Clin Pharmacol. 2007;63(2):232–7.CrossRefPubMedGoogle Scholar
  9. 9.
    van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem. 2002;48(10):1668–71.PubMedGoogle Scholar
  10. 10.
    Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001;69(3):169–74.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Maren I. Blonk
    • 1
  • Nathalie van der Velde
    • 2
  • Patricia M. L. A. van den Bemt
    • 1
    • 3
  • Ron H. N. van Schaik
    • 4
  • Tischa J. M. van der Cammen
    • 2
    Email author
  1. 1.Department of Hospital PharmacyErasmus University Medical CenterRotterdamThe Netherlands
  2. 2.Department of Internal Medicine, Section of Geriatric MedicineErasmus University Medical CenterRotterdamThe Netherlands
  3. 3.Division Pharmacoepidemiology and PharmacotherapyUtrecht Institute for Pharmaceutical SciencesUtrechtThe Netherlands
  4. 4.Department of Clinical ChemistryErasmus University Medical CenterRotterdamThe Netherlands

Personalised recommendations